ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer (EROS)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
80 participants
Aug 5, 2024
OBSERVATIONAL
Conditions
Summary
Although many phase III clinical trials evaluate the quality of life as a secondary endpoint, male sexuality remains a neglected topic in oncology research. In light of the long-term efficacy of new-generation anticancer treatments for ANSCLC (i.e. targeted therapies and immunotherapy), there is a paucity of data about any detrimental effect on fertility and sexuality that could complicate the therapy proposal, especially in young patients. The aim of this trial is to assess incidence of endocrine toxicity and sexual dysfuction in male patients receiving active treatment for ANSCLC
Eligibility
Inclusion Criteria6
- Diagnosis of advanced/metastatic NSCLC
- To be candidate to active treatment
- Aged ≥ 18 anni (up to 75 years old)
- To be sexually active in last 30 days before treatment start
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Written informed consent
Exclusion Criteria8
- History of endocrine disorders, excepting for controlled hypothyroidism (surgical or non-surgical) treated with replacement levothyroxine since at least 2 years
- Any cancer-related or medical condition that would interfere with the patient reported outcomes or laboratory assessment. Examples include, but are not limited to:
- Cancer-related conditions that may preclude/undermine sexual activity (e.g. leptomeningeal carcinomatosis, pathological vertebral fractures, gonadic metastases, unstable spinal cord compression, uncontrolled neurological symptoms, surgical complications):
- History of chronic liver disease or hormonal replacement therapy (e.g. ADT for prostatic cancer)
- Participants who not adequately recovered from previous confirmed chemotherapy-induced gonadotoxicity (e.g. cisplatin)
- Chronic use of drugs with known effect on male sexuality, including opiates, anxiolytics, antidepressants, mood stabilizers, beta blockers (e.g. atenolol) and high dose diuretics
- Psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
- Major psychological disorder and/or high distress level that would interfere with sexual function and the participant's ability to cooperate with the requirements of the study
Interventions
Alectinib 600 mg/BID
180 mg/daily
100 mg/daily
80 mg/daily
960 mg/daily
150 mg/BID
2 mg/daily
160 mg/BID
200 mg intravenous every 21 days
350 mg intravenous every 21 days
240 mg intravenous every 14 days
AUC4/AU5 intravenous every 21 days
500 mg/mq intravenous every 21 days
175 mg/mq intravenous every 21 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06532149